Drug Profile
Research programme: bladder cancer therapeutics - Serometrix
Alternative Names: SX-MTR1Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Serometrix
- Class Antineoplastics
- Mechanism of Action MTOR protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Bladder-cancer in USA
- 12 Jul 2016 Early research in Bladder cancer in USA (unspecified route)